Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue

Inclusion Criteria:

Patient is a consenting female age 40-75 years
Patient is scheduled for routine screening DBT
Patient is asymptomatic for breast disease
Patient had heterogeneously dense or extremely dense breasts on most recent prior mammography examination (Breast Imaging Reporting and Data System [BI-RADS] c or d) within 24 months of enrollment
Patient is able to participate fully in all aspects of the study (completing study visits and study data collection)
Patient understands and signs the study informed consent
Patient anticipates being able to return one year after study enrollment to complete the second round of screening

Exclusion Criteria:

Patient is currently pregnant or plans to become pregnant during the course of the study
Patient is currently lactating
Patient has had a prior MBI
Patient has had a prior whole breast ultrasound (WBUS) for screening, with either a hand-held ultrasound probe or automated system, within 12 months prior to study enrollment
Patient has had a prior breast MRI
Patient has had a prior contrast-enhanced mammogram (contrast enhanced spectral mammography [CESM] or contrast-enhanced digital mammography [CEDM])
Patient is concurrently participating in any other breast imaging research studies that involve undergoing additional breast imaging tests beyond routine screening with mammography, including but not limited to contrast-enhanced mammography, WBUS, MBI, or contrast-enhanced breast MRI
Patient has had a breast biopsy within 3 months prior to study enrollment
Patient has had breast surgery within 12 months prior to study enrollment
Patient is currently undergoing treatment for breast cancer or planning surgery for a high-risk breast lesion (atypical ductal hyperplasia [ADH], atypical lobular hyperplasia [ALH], lobular carcinoma in situ [LCIS], papilloma, radial scar)
Patient is currently taking a chemoprevention agent for breast cancer risk reduction or osteoporosis prevention (tamoxifen, raloxifene, anastrazole, letrozole, exemestane)
Patient has a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence